Human VEGF-A FlowCytomix Simplex

Description: This FlowCytomix Simplex Kit is designed for the measurement of Human VEGF-A in an immunoassay analyzed on a flow cytometer. Together with the FlowCytomix Human Basic Kit (cat. BMS8420FF), this kit can be used to detect VEGF-A alone or can be multiplexed with other Simplex Kits to measure a variety of analytes.

This kit contains bead population B2.

One of the key molecules for angiogenesis and for the survival of the endothelium is vascular endothelial growth factor (VEGF-A). It is a specific endothelial cell mitogen and a strong vascular permeability factor (VPF).
VEGF-A is a heparin-binding glycoprotein, secreted as a homodimer of 45 kDa by many different cell types. VEGF-A also causes vasodilation through the nitiric oxide synthase pathway in endothelial cells and can activate migration in monocytes. Many different splice variants of VEGF-A have been described, but VEGF165 is the most predominant protein and anchors with its heparin binding domain to extracellular matrix and to heparin sulfate.

Examples where VEGF-A plays an important role are psoriasis andrheumatoid arthritis, as well as the ovarian hyperstimulation syndrome. Diabetic retinopathy is associated with high intraocular levels of VEGF-A, and inhibition of VEGF-A function may result in infertility by blockage of corpus luteum function. Direct demonstration of the importance of VEGF-A in tumor growth has been achieved using dominant negative VEGF receptors to block in vivo proliferation, as well as blocking antibodies to VEGF or to one of the VEGF receptors. VEGF-A transcription is highly activated by hypoxia and by oncogenes like H-ras and several transmembrane tyrosine kinases, such as epidermal growth factor receptor and ErbB2. Together these pathways account for a marked upregulation of VEGF-A in tumors compared to normal tissues and are often of prognostic importance and relevance. Targeting the VEGF signalling may be of major therapeutic importance for many diseases and serves as a basis for the design of future (anti)-angiogenic treatments.

References: Plate,K.H.; Breier,G.; Weich,H.A.; Risau,W.. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848. (Link)

Neulen,J.; Yan,Z.; Raczek,S.; Weindel,K.; Keck,C.; Weich,H.A.; Marme,D.; Breckwoldt,M.. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J.Clin.Endocrinol.Metab 1995;80:1967-1971. (Link)

Rodriguez-Garcia,M.I.; Fernandez,J.A.; Rodriguez,A.; Fernandez,M.P.; Gutierrez,C.; Torre-Alonso,J.C.. Annexin V autoantibodies in rheumatoid arthritis. Ann.Rheum.Dis. 1996;55:895-900. (Link)

Arbiser,J.L.; Moses,M.A.; Fernandez,C.A.; Ghiso,N.; Cao,Y.; Klauber,N.; Frank,D.; Brownlee,M.; Flynn,E.; Parangi,S.; Byers,H.R.; Folkman,J.. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc.Natl.Acad.Sci.U.S.A 1997;94:861-866. (Link)

Gasparini,G.; Toi,M.; Gion,M.; Verderio,P.; Dittadi,R.; Hanatani,M.; Matsubara,I.; Vinante,O.; Bonoldi,E.; Boracchi,P.; Gatti,C.; Suzuki,H.; Tominaga,T.. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J.Natl.Cancer Inst. 1997;89:139-147. (Link)

Carmeliet,P.; Collen,D.. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr.Top.Microbiol.Immunol. 1999;237:133-158. (Link)

Risau,W.. Mechanisms of angiogenesis. Nature 1997;386:671-674. (Link)

Klaus,G.G.; Choi,M.S.; Lam,E.W.; Johnson-Leger,C.; Cliff,J.. CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. Int.Rev.Immunol. 1997;15:5-31. (Link)

Weindel,K.; Moringlane,J.R.; Marme,D.; Weich,H.A.. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis?. Neurosurgery 1994;35:439-448. (Link)

Senger,D.R.; Galli,S.J.; Dvorak,A.M.; Perruzzi,C.A.; Harvey,V.S.; Dvorak,H.F.. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985. (Link)